

## GENERAL INFORMATION

### CONGRESS VENUE

Royal Hotel Carlton  
Via Montebello, 8  
40121 Bologna, Italy  
www.royalhotelcarltonbologna.com

### OFFICIAL LANGUAGE

English

### REGISTRATION

Registration is free and it is available  
at [www.ercongressi.it](http://www.ercongressi.it) - section  
“I nostri congressi/anno 2026”

### CME

An application for Italian CME credits has been  
made as follows:

- Provider Studio ER Congressi SRL: ID 828- 476838
- **No. 4,9 CME credits** for physicians  
(disciplines: hematology, oncology)
- Educational objective: “guidelines-protocols-  
procedures”

### SCIENTIFIC SECRETARIAT

Antonio Curti  
IRCCS Azienda Ospedaliero-Universitaria di Bologna,  
Istituto di Ematologia “Seràgnoli”, Bologna

### ORGANIZING SECRETARIAT

Studio E.R. Congressi  
Via De' Poeti 1/7 - 40124 Bologna, Italy  
Phone +39 051 4210559  
E-mail: [ercongressi@ercongressi.it](mailto:ercongressi@ercongressi.it)  
[www.ercongressi.it](http://www.ercongressi.it)



ER Congressi

With the unrestricted educational grant of

Johnson & Johnson



Auspices  
SIE – Società Italiana di Ematologia  
SIES – Società Italiana di Ematologia Sperimentale

# 2nd BOLOGNA WORKSHOP on IMMUNOTHERAPY FOR ACUTE MYELOID LEUKEMIA

Bologna, Royal Hotel Carlton  
September 29-30, 2026



**14.00 Welcome**

*M. Seri (Bologna), P.L. Zinzani (Bologna)*

**14.10 Rationale and goals of the workshop**

*A. Curti (Bologna)*

**14.20 Lecture**

Chairman: *P.L. Zinzani (Bologna)*

**Clonal evolution in myeloid neoplasms and inflammatory stromal remodeling: implications for immunotherapy**

*M.H.G.P. Raaijmakers (Rotterdam, The Netherlands)*

**SESSION 1**

**INSIDE OUT: HOW CELL-INTRINSIC FEATURES OUTBREAK AML IMMUNE MICROENVIRONMENT**

Chairmen: *A. Curti (Bologna), F. Pane (Napoli)*

**14.50 Leukemia hematopoietic hierarchies and differentiation state**

*S. Renders (Heidelberg, Germany)*

**15.10 AML genomic landscape: focus on IDH1 and FLT3**

*J. Nanni (Bologna)*

**15.30 Leukemia epigenetic remodelling: the lesson of allogeneic stem cell transplantation**

*L.A.E. Vago (Milan)*

**15.50 Epithelial-to-mesenchymal transition**

*S. Sangaletti (Milan)*

**16.10 Leukemic cell metabolic profile**

*G. Simonetti (Meldola-FC)*

**16.30 Coffee break**

**SESSION 2**

**WHICH ARE THE HALLMARKS OF AML IMMUNE MICROENVIRONMENT?**

Chairmen: *A. Curti (Bologna), M.G. Della Porta (Rozzano-MI)*

**16.50 Inflammation and T-cell dysfunctionality**

*S. Rutella (University of Sheffield, UK)*

**17.10 Reprogramming the cytotoxic architecture of NK cells to sustain functional persistence**

*K.J. Malmberg (Oslo, Norway)*

**17.30 Bone marrow immune cells aggregation**

*O. Heidenreich (Utrecht, The Netherlands)*

**17.50 Immune dysregulation dominance and poor outcome: when MDS looks like AML**

*S. Kordasti (London, UK)*

**18.10 Aging and immune bone marrow microenvironment**

*C. Waskow (Jena, Germany)*

**8.45 Introduction of the second day of scientific works**

**SESSION 3**

**SO WHAT? HOW TO MOVE A STEP FORWARD INTO THE CLINICS**

Chairmen: *A. Curti (Bologna), A. Venditti (Roma)*

**9.00 Dendritic cell immunotherapy in myeloid leukemia**

*B.T. Gjertsen (Bergen, Norway)*

**9.20 AML-directed CAR-T cell therapies: where we stand**

*M. Subklewe (Munich, Germany)*

**9.40 Combination backbone for immunotherapies: focus on Aza-Ven**

*A. Curti (Bologna)*

**10.00 Menin inhibition: immunological effects and implications for future immunotherapies**

- **NPM1 and immune microenvironment**

*M.P. Martelli (Perugia)*

- **Menin inhibitors**

*C. Papayannidis (Bologna)*

**10.45 Coffee break**

**SESSION 4**

**NOVEL TOOLS, PARADIGMS AND PERSPECTIVES: IN SEARCH OF IMMUNOLOGICAL BIOMARKERS**

Chairmen: *A. Curti (Bologna), D. Forte (Bologna)*

**11.00 Spatial omics**

*J. Schröder (Tübingen, Germany)*

**11.20 Amino acids and tryptophan metabolites**

*C.A. Opitz (Heidelberg, Germany)*

**11.40 3D models**

*U. Rietskina (Riga, Latvia)*

**12.00 Extracellular vesicles**

*D. Forte (Bologna)*

**12.20 Real-time immunometabolism**

*R.J. Argüello (Marseille, France)*

**12.40 Final discussion and concluding remarks**

*A. Curti (Bologna)*

